3237results about "Specific peptides" patented technology

The invention provides a preparation method of a novel recombinant humanized collagen hydrogel. The method comprises the following steps: recombinant humanized collagen and a dialdehyde crosslinking agent are subjected to a reaction, the concentration of the dialdehyde crosslinking agent is 0.01-0.25%, and the recombinant humanized collagen is one or more of recombinant humanized type II collagen, recombinant humanized type III collagen and recombinant humanized type XVII collagen, and the recombinant humanized collagen has a triple helix structure. The aldehydes cross-linking agent suitable for the recombinant humanized collagen, especially the recombinant humanized collagen with a triple helix structure, and the optimal reaction conditions are determined.

The invention relates to a nano antibody targeting cadherin 17 and application thereof, and relates to the technical field of immunology and molecular biology, the amino acid sequence of a complementary determining region of the nano antibody targeting cadherin 17 comprises CDR1 shown as any one of SEQ ID NO: 21-32, CDR2 shown as any one of SEQ ID NO: 34-45, and CDR3 shown as any one of SEQ ID NO: 47-58. According to the invention, an alpaca immune phage display library is constructed, a series of nano antibody molecules targeting cadherin 17 (CDH17) are screened from the alpaca immune phage display library, and functions and applications of the nano antibody are verified at various levels of CDH17 antigen protein, CDH17 target cells, CDH17 CAR-T cells and the like.

The invention relates to a high-activity recombinant XVII type collagen as well as a rapid preparation method and application thereof, and belongs to the technical field of bioengineering. The amino acid sequence of the high-activity recombinant XVII type collagen is as shown in SEQ ID NO. 1, and the nucleotide sequence of the high-activity recombinant XVII type collagen is as shown in SEQ ID NO. 2. The invention also provides a preparation method and application of the recombinant XVII type collagen. The high-activity recombinant XVII type collagen has good biological activity, has good effects of promoting cell adhesion, cell proliferation and cell migration, and can be compounded with other proteins to form raw materials of tissue engineering products, cosmetics, health care products or medicines. The high-activity recombinant XVII type collagen gene is integrated to different positions of a yeast genome through three different vectors, and the copy number of a target gene is increased, so that the expression quantity of the recombinant XVII type collagen is remarkably increased, and the yield of the high-activity recombinant XVII type collagen is effectively increased.

The present disclosure provides new prime editor guide RNAs for prime editing, constructs for prime editing, and methods for using same. In addition, the present disclosure provides compositions and methods for conducting prime editing of a target DNA molecule (e.g., a genome) that enables the incorporation of a nucleotide change and / or targeted mutagenesis (e.g., insertion or deletion). The nucleotide change can include a single-nucleotide change (e.g., any transition or any transversion), an insertion of one or more nucleotides, or a deletion of one or more nucleotides. More in particular, the disclosure provides fusion proteins comprising nucleic acid programmable DNA binding proteins (napDNAbp) and a polymerase (e.g., reverse transcriptase), which is guided to a specific DNA sequence by a prime editor RNA (PEgRNA). The prime editor guide RNA comprises an extension arm that provides a DNA synthesis template sequence which encodes a single strand DNA flap, which is homologous to an endogenous DNA sequence, but which contains the desired one or more nucleotide changes and which, following synthesis by the polymerase (e.g., reverse transcriptase), becomes incorporated into the target DNA molecule.

The invention relates to a humanized nano antibody targeting cadherin 17 and application of the humanized nano antibody, and relates to the technical field of immunology and molecular biology. The complementarity determining region of the humanized nano antibody comprises a CDR1 of which the amino acid sequence is shown as SEQ ID NO: 2, a CDR2 of which the amino acid sequence is shown as SEQ ID NO: 4 and a CDR3 of which the amino acid sequence is shown as SEQ ID NO: 6; a framework region of the humanized nano antibody comprises an FR1 of which the amino acid sequence is shown as any one of SEQ ID NO: 1 and SEQ ID NO: 8, an FR2 of which the amino acid sequence is shown as any one of SEQ ID NO: 3, SEQ ID NO: 9 and SEQ ID NO: 11, an FR3 of which the amino acid sequence is shown as any one of SEQ ID NO: 5 and SEQ ID NO: 10, and an FR4 of which the amino acid sequence is shown as SEQ ID NO: 7. According to the humanized nano-antibody, the immunogenicity of the nano-antibody is reduced, the targeted binding activity and killing activity are improved, and the humanized nano-antibody can be used for developing immunodetection reagents, CAR-T / NK cell drugs and antibody drugs.

The present invention relates to T lymphocytes targeting CLD18A2 and a preparation method and application thereof. The inventors have successfully found a target gene CLD18A2 suitable for developing CAR T cells from a number of tumor-related genes for the first time, and successfully prepared CAR T cells targeting CLD18A2, thereby providing a new treatment method for pancreatic cancer, gastric cancer and other tumors.

The invention provides recombinant VIII type humanized collagen and application thereof, and the recombinant VIII type humanized collagen is of a triple helix structure, has good cell adhesion activity, does not generate immunological rejection and anaphylactic reaction when being applied to a human body, is a brand new human body synthetic biological material, and has good application prospects.

The invention provides a nano photosensitizer modified by outer membrane vesicles of genetically engineered bacteria as well as a preparation method and application of the nano photosensitizer. The nano photosensitizer is a nano material with the particle size of 80-120 nm, and the nano photosensitizer modified by the genetically engineered bacterium outer membrane vesicle comprises dipalmitic acid phosphatidylcholine (DPPC), distearoyl phosphatidylcholine (DSPC), dioleoyl lecithin (DOPC), cholesterol, a small molecule dye and CD47nb-OMV membrane protein. The chemical structure of the small molecule dye is shown as a formula I or a formula II. The nano photosensitizer OBDlp modified by outer membrane vesicles of genetically engineered bacteria serves as a novel nano photosensitizer, tumor targeting PTT is mediated through NIR II FL / PA imaging, tumor immunogenicity is improved, antigen presenting cells are activated, and infiltration and functionalization of CD8 + T cells are caused. And OBDlp and laser are combined to induce release of a large amount of DAMPs and trigger ICD to promote maturation of cDC1s. Meanwhile, a CD47 nano antibody carried by the nano photosensitizer induces polarization of M1 phenotype macrophages by blocking a CD47-SIRP alpha signal transduction axis, and an immunosuppression tumor microenvironment is reversed.

Provided are methods of generating chimeric antigen receptors (CAR). In some embodiments, library screening of CAR is performed by generating a vector encoding the CAR from random attachment of vectors from libraries of vectors encoding antigen-binding domains (e.g., scFv regions), hinge regions, and endodomains. In some embodiments, the vectors contain a transposon.

Compositions and methods are provided herein for conducting prime editing of a target DNA molecule (e.g., a genome) that enables the incorporation of a nucleotide change and / or targeted mutagenesis. The compositions include fusion proteins comprising nucleic acid programmable DNA binding proteins (napDNAbp) and a polymerase (e.g., reverse transcriptase), which is guided to a specific DNA sequence by a modified guide RNA, named an PEgRNA. The PEgRNA has been altered (relative to a standard guide RNA) to comprise an extended portion that provides a DNA synthesis template sequence which encodes a single strand DNA flap which is synthesized by the polymerase of the fusion protein and which becomes incorporated into the target DNA molecule.

The invention belongs to the technical field of genetic engineering, and particularly relates to recombinant human III-type collagen for promoting angiogenesis as well as a preparation method and application of the recombinant human III-type collagen. The recombinant human III-type collagen for promoting angiogenesis has an amino acid sequence as shown in SEQ ID NO. 1. Nine different sites of the full-length natural III-type collagen are replaced by GFOGER sequences which are from the I-type collagen and are specifically combined with integrin sites, the angiogenesis promoting function of the collagen is enhanced under the condition that the total length of natural full-length amino acid is not changed, and meanwhile, four natural integrin sites with low adhesion rate are also replaced; the recombinant III-type collagen has high adhesive force, so that angiogenesis is further promoted. By means of the transformation mode, the angiogenesis rate is increased by 37% or above, the molecular weight of the translated protein is moderate, and the translated protein is easy to prepare.

The invention belongs to the field of gene engineering. Specifically, the invention relates to a base editing system for optimizing engineered T cells and application of the base editing system. The present invention provides a base editing system for modifying engineered T cells, comprising: i) a base editing polypeptide, and / or an expression construct encoding a base editing polypeptide, the base editing polypeptide comprising a DNA binding protein and at least one deaminase domain; ii) a guide RNA, and / or an expression construct encoding a guide RNA, the guide RNA targeting any one of TRAC, TGFBR2, PD-1, CISH, and / or FAS genomic regions, or any combination thereof. The base editing system disclosed by the invention has high efficiency of a gene editing tool and low Indel frequency, can realize accurate editing of T cell function enhancement related genes, and has important value for expanding application scenes of a base editing technology in the fields of preparation of safe and efficient engineered T cells and the like.

The present invention relates to a p75NTR neurotrophin binding protein, p75NTR (NBP), for use in the treatment of pain and / or a symptom of pain.

The present invention relates to methods and compositions for reducing the immunogenicity of chimeric Notch receptors, and specifically to transcription factors useful for controlling gene expression delivered to tissues by such chimeric Notch receptors.

The invention belongs to the technical field of biological medicine and molecular biology, and particularly relates to a single-chain antibody targeting NRP1, a CAR-T cell and application of the single-chain antibody and the CAR-T cell in fibrosis treatment. Four types of high-affinity single-chain antibodies targeting mouse NRP1 antigens are obtained by immunizing mice, the single-chain antibodies are applied to second-generation CAR, T cells of mouse spleen sources are infected after virus packaging, and CAR-T cells are constructed. The CAR-T cells of the targeted NRP1 can be used for effectively killing NRP1 positive cells. In-vivo experiments show that the CAR-T cells can inhibit the growth of NRP1 positive tumor cells. The CAR-T cell can improve the mouse liver fibrosis condition, collagen in the mouse liver is reduced through treatment, and the molecular level of fibrosis markers SMA and NRP1 is reduced, it is indicated that the CAR-T cell recognizes and eliminates activated HSCs through targeting NRP1, and the fibrosis degree is reduced.

The invention belongs to the fields of gene engineering, bioengineering and biological medicine, and relates to a nucleic acid molecule for coding human defensin, a method for preparing the human defensin and application. The nucleic acid sequence of the nucleic acid molecule comprises any one of the following sequences: (1) a sequence as shown in SEQ ID NO.2; (2) a nucleic acid sequence for coding human defensin, which is obtained by substituting, deleting or adding one or more than two nucleotides to the sequence as shown in SEQ ID NO.2; and (3) a nucleotide sequence which has at least 80% sequence homology with the nucleotide sequence in (1) or (2) and has the same or similar functions with the nucleotide sequence in (1) or (2). According to the method provided by the invention, the recombinant expression vector is constructed by using nucleic acid molecules for coding the human defensin, the human defensin hBD-3 can be recombined and expressed, the recombinant fusion protein is released to the supernatant of a culture solution, the protein purification is convenient, the obtained recombinant human defensin has a tissue regeneration function, and a new active molecule is provided for the development of a novel drug.

The invention discloses a human albumin binding peptide 1E3 and application of the human albumin binding peptide 1E3 in promoting purification of human albumin, and belongs to the technical field of polypeptides. The human albumin binding peptide comprises an amino acid sequence as shown in SEQ ID NO. 1; and / or an amino acid sequence of a fusion protein with the same function, which is obtained by connecting tag protein to the N terminal and / or C terminal of the amino acid sequence as shown in SEQ ID NO.1. The human albumin binding peptide has extremely high affinity with human albumin and can be used for separating and purifying a human albumin solution, and the purity of the purified human albumin far exceeds the pharmacopoeia standard and can reach 99.99% or above. The method is good in safety and stable in process, and has a wide application prospect in the aspect of separation and purification of the human albumin.

The invention relates to the technical field of antibodies, in particular to a Trop2 combined nano antibody, a chimeric antigen receptor and application of the Trop2 combined nano antibody and the chimeric antigen receptor. The Trop2-binding nano antibody provided by the invention can efficiently and specifically recognize and bind Trop2 protein, and can be used for diagnosing and treating diseases taking Trop2 molecules as markers. The invention further provides CAR and CAR-T cells which are combined with the Trop2 protein, and the CAR-T cells have a good Trop2-targeting immune clearance effect, can be used for specifically recognizing and killing cells expressing Trop2, can be used for improving and treating diseases with Trop2 molecules as markers and have a good application prospect in tumor diagnosis and treatment.

The invention belongs to the field of gene engineering. Specifically, the invention relates to a system, a tool and a method for modifying or editing target nucleotide bases, and more specifically, the invention relates to an optimized QBE base editing system and application thereof. The base editing system disclosed by the invention has the advantages of high efficiency of a gene editing tool, high product purity, low Indel frequency, low off-target frequency and abundant gene editing windows, and has important value for expanding application scenes of a base editing technology in the fields of life science basic research, agriculture, biological medicine and the like.

Provided is an anti-BDCA2 antibody. The anti-BDCA2 antibody can bind to a BDCA2 antigen with high specificity, has high affinity, and can effectively inhibit CpG-A from stimulating PBMCs to secrete IFNa and IgM, and thus is expected to serve as a drug for treating autoimmune diseases.

Disclosed is a genetic diagnosis chip. The genetic diagnosis chip includes one or more unit processing parts, wherein the unit processing part includes a pretreatment unit that loads a sample and performs a pretreatment process on a target material in the loaded sample, and a distribution unit which is located radially outward from the pretreatment unit and in which the target material pretreated through the pretreatment unit is distributed and detection of the distributed target material is performed, the pretreatment unit includes a sample loading unit that loads the sample, and a capture channel which captures the target material from the loaded sample, and the sample loading unit is formed on the capture channel.

The present application relates to systems and methods to generate B cells genetically modified to express selected antibodies. The systems and methods can be used to: eliminate the need for classical vaccination; providing protection against infections available for current vaccination; providing protection against infections when the patient is additionally subjected to immunosuppression; and / or provides benefits provided by therapeutic antibodies, such as in the treatment of autoimmune disorders.

To provide polypeptides, such as fibronectin type III (FN3) domains that can bind CD71, their conjugates, isolated nucleotides encoding the molecules, vectors, host-cells, and further to provide methods of making and using the same.SOLUTION: Provided are: polypeptides including specific sequences or an amino acid sequence that is at least 90% identical to an amino acid sequence of any combination thereof; or a polypeptide including specific sequences or an amino acid sequence of any combination thereof. In some embodiments, an FN3 domain does not naturally exist. In some embodiments, the FN3 domain binds to human CD71 at a site on CD71 that does not compete with transferrin binding to CD71.SELECTED DRAWING: None

Compositions, methods and systems for targeted delivery using one or more shuttles operably linked to one or more cargos (e.g., cargo polypeptides, e.g., cargo oligonucleotides) and subsequent quantification of an abundance of one or more cargos (e.g, proteins) in a mixture (e.g., a complex mixture (e.g., in vivo)) or in a specific cell, tissue, or organ of interest (e.g., in vivo) using barcodes (e.g., peptide barcodes), binders (e.g., polypeptide binders), and binding agents (e.g., phage) are provided herein.

The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.

The present invention provides a novel antithrombotic antibody, which targets FIXa and has unique properties, specifically targets the binding site of blood coagulation factors FIXa and FVIIIa, reduces the formation of FVIIIa-FIXa complex, blocks the conversion of FX to FXa, and exerts antithrombotic effects. The antibody of the present invention has suitable antithrombotic properties, has a wide effective therapeutic concentration window, but does not increase the risk of bleeding; it can realize the demand for moderate antithrombotic properties in clinical applications and effectively avoid bleeding problems caused by excessive effects. The present invention also discloses a method for screening drugs that target the FIXa-FVIIIa binding site.

The present disclosure provides improved compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.

The present disclosure provides drug-responsive domains derived from human carbonic anhydrase 2 that can modulate the protein stability of human interleukin-15 (IL15) payloads, as well as compositions and methods of use thereof.

Compositions and methods are provided herein for conducting prime editing of a target DNA molecule (e.g., a genome) that enables the incorporation of a nucleotide change and / or targeted mutagenesis. The compositions include fusion proteins comprising nucleic acid programmable DNA binding proteins (napDNAbp) and a polymerase (e.g., reverse transcriptase), which is guided to a specific DNA sequence by a modified guide RNA, named an PEgRNA. The PEgRNA has been altered (relative to a standard guide RNA) to comprise an extended portion that provides a DNA synthesis template sequence which encodes a single strand DNA flap which is synthesized by the polymerase of the fusion protein and which becomes incorporated into the target DNA molecule.

The invention relates to the technical field of synthetic biology, in particular to polypeptide with a triple helix structure, recombinant XII type humanized collagen and application of the recombinant XII type humanized collagen. The recombinant XII type humanized collagen is successfully expressed and prepared, has a triple-helix structure and good biological activity including promotion of cell proliferation activity, cell adhesion activity and inhibition of MMP-1, is used as a biological material derived from a human body, does not generate immunological rejection and anaphylactic reaction when applied to the human body, and has a good application prospect. The composition can be used for medical or non-medical application of a plurality of tissues and organs of a human body, filling, compatibilizing or repairing, and promotion of skin compactness or wrinkle resistance and other scenes.